Research and Markets: Benchmarking Drug Safety and Pharmacovigilance

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/fe7e34/benchmarking_drug) has announced the addition of Cutting Edge Information's new report "Benchmarking Drug Safety and Pharmacovigilance" to their offering.

This is a one-of-a-kind study dedicated exclusively to drug safety and pharmacovigilance. Benchmarking Drug Safety and Pharmacovigilance is a data-driven guide to optimizing your company's drug safety efforts. Designed for drug safety teams that work with clinical and post-marketed products, this study details budgets and outsourcing, structure and staffing, activities, timing, and communications. Beyond quantitative analysis, top executives reveal best practices, creative solutions to ongoing challenges, and their unique perspectives on current trends.

Benchmarking Drug Safety and Pharmacovigilance provides best practices for pharmaceutical and biotechnology teams to structure their drug safety teams, develop pharmacovigilance strategies, allocate budgets and headcounts appropriately, and learn when to initiate critical pharmacovigilance activities. Explore real-company strategies and metrics for companies drug safety and pharmacovigilance teams:

  • Learn what it means to develop a strategic drug safety team: Many drug company executives view drug safety as a required function or as nothing more than a cost center. This study uncovers best practices that top-notch drug safety and pharmacovigilance teams have in place to deliver strategic impact.
  • Optimize your drug safety team: Several factors affect the size and structure of drug safety and pharmacovigilance teams. This study shows how to align your team, assign responsibility for investigational and post- market products, determine the most appropriate activities to outsource, and understand how to choose among drug safety vendors.
  • Prove the drug safety teams value: Performance measurement for pharmacovigilance activities are few and far between. So how does a drug safety team demonstrate its impact to the bottom line? This study showcases best practices to measure and prove the value of a strategic drug safety team.

Key Topics Covered:

  • Executive Summary
  • Study Methodology
  • Study Definitions
  • Profiled Companies
  • Five Key Findings and Recommendations
  • Drug Safety Budgets and Outsourcing
  • Drug Safety Budgets
  • Outsourcing Pharmacovigilance Needs
  • Structure and Staffing
  • Drug Safety Structures
  • Drug Safety Staffing
  • Drug Safety Activities
  • Activities Timeline
  • Internal Processes
  • Interaction with the FDA
  • Adverse Event Databases

Companies Mentioned:

  • Abbott Laboratories
  • Bausch and Lomb
  • Cerexa
  • ClinQuest Inc.
  • Cubist Pharmaceuticals
  • Drug Safety Alliance (DSA)
  • Elan
  • Ferring Pharmaceuticals
  • Genzyme
  • GlaxoSmithKline
  • InterMune Pharmaceuticals
  • Isis Pharmaceuticals
  • Jazz Pharmaceuticals
  • Johnson & Johnson
  • Labopharm
  • Novartis
  • Ortho-McNeil Janssen
  • Otsuka
  • Pfizer
  • Progenics Pharmaceuticals
  • Solvay
  • Stromedix
  • Taro
  • Vical Inc.
  • ViroPharma
  • VIRxSYS
  • ZARS Pharma
  • ...plus more

For more information visit http://www.researchandmarkets.com/research/fe7e34/benchmarking_drug



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.